🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis

RecruitingPhase 2Ages 18 Years - anyAllJena University Hospital
NCT03993262 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Autoimmune Encephalitis is a disorder of the central nervous system caused by bodily substances, called antibodies. Antibodies normally help the body to prevent infections. However, in this disorder, the antibodies turn against the body itself and especially against cells in the brain and disturb the normal brain function. They are therefore called autoantibodies. There is no specific therapy for patients with autoimmune encephalitis so far. At the moment, the symptoms are treated with approved medications such as cortisone and immunotherapies also used in oncology. These therapies are unspecified and aim to reduce the number of autoantibodies and to contain the autoimmune process. In this trial we aim to test a new therapy option: in this therapy the body cells producing autoantibodies will be specifically targeted by a substance called bortezomib. The trial addresses patients with se

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Clinically diagnosed severe autoimmune encephalitis (defined as mRS ≥ 3) with autoantibodies to neuronal surface proteins in cerebrospinal fluid and / or serum * Pretreatment with rituximab * Age ≥18 years * signed informed consent * Women of childbearing potential (up to 2 years after menopause): negative pregnancy test Exclusion Criteria: * pregnancy/breast-feeding * acute infiltrative pulmonary and pericardial disease * malignant tumor under current chemotherapy * Simultaneous participation in another intervention study * Previous participation in this study * Known hypersensitivity to an ingredient of the investigational product * Continued therapy with glucocorticoids / rituximab during the study duration (last dose must be administered before the first dose of the investigational product)
💊

What it tests

  • Bortezomib
  • Placebo
📍

Where

17 sites
Ludwig-Maximilians-Universität München, Klinikum Großhadern
München, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Universitätsklinikum Jena, Sektion Translationale Neuroimmunologie, Klinik für Neurologie
Jena, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Charité - Universitätsmedizin Berlin, Klinik für Neurologie mit Experimenteller Neurologie
Berlin, Germany
Ruhr-Universität Bochum, St. Josef Hospital, Klinik für Neurologie
Bochum, Germany
University Hospital Düsseldorf, Clinic for Neurology
Düsseldorf, Germany
Universitätsklinikum Erlangen, Neurologische Klinik
Erlangen, Germany

…and 9 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy